Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oncolys BioPharma (TSE:4588) Total Current Assets Explanation
In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.
Oncolys BioPharma's Liquidation Value for the quarter that ended in Dec. 2025 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncolys BioPharma Total Current Assets Related Terms
Oncolys BioPharma Total Current Assets Historical Data
* Premium members only.
The historical data trend for Oncolys BioPharma's Total Current Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.
What does a Total Current Assets of 円4,494.35 Mil mean?
Oncolys BioPharma (TSE:4588) has a Total Current Assets of 円4,494.35 Mil as of Dec. 2025. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Oncolys BioPharma and its competitors.
Is Oncolys BioPharma's Total Current Assets too high?
Oncolys BioPharma's current Total Current Assets is 円4,494.35 Mil. Overall, Oncolys BioPharma has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oncolys BioPharma's Total Current Assets compare to VRTX and REGN?
Oncolys BioPharma's Total Current Assets of 円4,494.35 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Assets for a Biotechnology company?
A good Total Current Assets depends on the Biotechnology industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Assets mean?
A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Oncolys BioPharma and its competitors. Oncolys BioPharma's current Total Current Assets is 円4,494.35 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncolys BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Oncolys BioPharma (TSE:4588) is currently considered Significantly Overvalued. The stock's GF Value™ is 円363.11, compared to a current price of 円2,501.00 — trading 588.8% above its estimated fair value. The current Total Current Assets is 円4,494.35 Mil. Oncolys BioPharma's overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Assets calculated?
Total Current Assets is calculated from a company's financial statements. For Oncolys BioPharma (TSE:4588), the current Total Current Assets is 円4,494.35 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncolys BioPharma (TSE:4588) Overvalued in 2026?
Based on GuruFocus' analysis, Oncolys BioPharma stock appears to be overvalued.
The current stock price of 円2,501.00 is trading 588.8% above its estimated GF Value™ of 円363.11.
GuruFocus considers Oncolys BioPharma to be Significantly Overvalued.
Key valuation signals for TSE:4588:
Total Current Assets: 円4,494.35 Mil
GF Value™: 円363.11 vs. price of 円2,501.00 (588.8% above fair value)
No single metric tells the full story. See the TSE:4588 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncolys BioPharma Inc develops pharmaceutical products. The company is a biopharmaceutical company focused on developing therapies for cancer treatment. Their product pipeline includes various drug candidates such as Telomelysin (OBP-301) and OBP-702, aimed at addressing unmet medical needs in oncology. The company targets healthcare providers and institutions involved in cancer care and research.
40GF Score
Get the complete analysis for TSE:4588
Total Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4588 has been successfully added to your 
